{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02654587\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["OSE2101"]],"indication":"HLA-A2-positive advanced NSCLC after immune checkpoint inhibitor failure","name":"ATALANTE-1","nct_id":"NCT02654587","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=atalante-1-nct02654587. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ATALANTE-1","arms":[{"description":"OSE2101 was administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit of OSE2101. OSE2101 dose was 5 mg of peptides (0.5 mg for each peptide).","label":"OSE2101","type":"EXPERIMENTAL"},{"description":"Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.\n\nPatients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.\n\nDocetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal.","label":"Docetaxel or Pemetrexed","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2021-01-15","type":"ACTUAL"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":219,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"OSE2101","otherNames":["TEDOPI","EP-2101","EP2101","IDM-2101"],"type":"BIOLOGICAL"},{"name":"Docetaxel","otherNames":["Taxotere"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["Alimta"],"type":"DRUG"}],"last_update":"2024-02-02","lead_sponsor":"OSE Immunotherapeutics","official_title":"A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2021-01-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Approx. 24 months"}],"references":[{"citation":"Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G; ATALANTE-1 study group. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 Sep 11.","pmid":"37704166","type":"RESULT"}],"start_date":{"date":"2016-02-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure","url":"https://clinicaltrials.gov/study/NCT02654587"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/atalante-1-nct02654587"}